Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
about
Human immunodeficiency virus type-1 episomal cDNA in semen.Infection of semen-producing organs by SIV during the acute and chronic stages of the diseaseIndividualization of antiretroviral therapy--pharmacogenomic aspectQuantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy.HIV infection of the male genital tract--consequences for sexual transmission and reproduction.A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineageInfluence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTHIV dynamics in seminal plasma during primary HIV infectionTreatment to prevent transmission of HIV-1Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceEffect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a.Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyRaltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitroDetection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral TherapyImperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationA review of nelfinavir for the treatment of HIV infection.HIV pharmacology: barriers to the eradication of HIV from the CNS.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Overcoming pharmacologic sanctuaries.Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo.High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic developmentThe pharmacokinetics and viral activity of tenofovir in the male genital tractAntiretroviral bioanalysis methods of tissues and body biofluids.Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
P2860
Q24813631-E94A9277-56A4-44AC-B4C6-6F1A1DA7942CQ27301766-A8974F92-A9A0-445F-BF78-74FF4819FDADQ28070574-D3F1D107-6755-47FC-866C-E7098786B923Q31135042-4A7C7BF9-841A-4C02-B532-D963AF91688DQ33405725-975D55E1-7894-4C11-A818-096BA7B942D9Q33629797-5A56B2D6-F24E-405E-A147-001F8993D68AQ33728690-8DC036FA-4A78-4076-946E-6368191FF70AQ33786313-7B478FD4-EDBA-4E08-890A-0C40137861EEQ33821263-9058B1E2-5D43-4B1C-BDEE-0467AF853348Q33864438-432CAEA9-C096-437E-AEBA-B93FB3D91386Q34012749-4CE1DF0E-DD07-41C0-8B92-01D6479B82DDQ34083267-193C4271-7F74-4512-87E5-EFF5A00DC7C3Q34102424-4344820B-9A0A-4245-9914-6D05B8615BFBQ34138487-C54E23E9-2CCE-4970-88CE-25F35BA5CFDCQ34203175-9ADFC956-45A1-4C8E-ACA1-FCBB1D402443Q34472532-DB716597-372E-4878-BB23-F3D176E19D70Q34869449-C2A7AC18-2413-45C9-9EE4-7BE2C7281F54Q35264750-210A7CA2-E8F0-45AD-A7DF-79EDC6B898F3Q35385630-1D4D6B83-1FCC-4A1E-8FFE-6FA8AC32A1DBQ35547967-D35E5664-7CAA-40D1-80BD-0BA6A174A699Q35569867-FD1B9893-F269-44F7-804C-7F16F477019AQ35641179-B7827C8D-9AC1-4BD1-A747-2D36F54DC627Q35699612-EE801709-9F21-403A-B830-AEE2D53F6026Q35882795-2E6F56D3-A1A8-493C-80C5-BAFF4D991693Q35993707-B666A40A-4678-40E8-877F-6A10E0C93C89Q36222013-2C539B9A-0883-49E5-8349-08472841E183Q36330062-B4E8B5B1-3D0E-4906-9044-D4A2C1C5C00DQ36546278-A6627DFA-7FE1-4506-AA2E-DDEA35D6B991Q36552753-34A28555-5F54-40DD-98C1-FA9493292E38Q36723780-F2C16997-45BB-4EA4-B76D-4031C76DEBA9Q36915933-ABC5D3A3-162C-4F6C-84E7-5D90D2E431A9Q36954674-ABBFE038-106C-4EE7-8073-84A9EC51DDDFQ37013364-9A9D0C16-8109-41E3-9977-24D6909AEB94Q37112072-AE253610-A2D1-4C09-A573-0D8B82CB0F33Q37123276-B70F8FB0-46F6-4046-9152-9211C98029E0Q37127522-108174D2-1E67-4697-B765-5B1D5CF6CA6DQ37304746-F8FEBA8C-6CBA-46B5-858A-CBCDFDB6E650Q37332868-D4B084AC-EFEF-4D23-93E4-CCA08DB7AFB1Q37333675-B77C8382-A827-4BD9-97DE-975FDC85B7D9Q37362444-BF298992-D076-4074-9E64-F015E31D7093
P2860
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Discrepancies between protease ...... iency virus-infected patients.
@ast
Discrepancies between protease ...... iency virus-infected patients.
@en
Discrepancies between protease ...... iency virus-infected patients.
@nl
type
label
Discrepancies between protease ...... iency virus-infected patients.
@ast
Discrepancies between protease ...... iency virus-infected patients.
@en
Discrepancies between protease ...... iency virus-infected patients.
@nl
prefLabel
Discrepancies between protease ...... iency virus-infected patients.
@ast
Discrepancies between protease ...... iency virus-infected patients.
@en
Discrepancies between protease ...... iency virus-infected patients.
@nl
P2093
P2860
P1476
Discrepancies between protease ...... iency virus-infected patients.
@en
P2093
Alain Lafeuillade
Bruno Lacarelle
Caroline Solas
Gilles Hittinger
Philippe Halfon
Stéphane Chadapaud
P2860
P304
P356
10.1128/AAC.47.1.238-243.2003
P407
P577
2003-01-01T00:00:00Z